The company has received approval from the US health regulator for the capsules in the strengths of 30 mg (base), 45 mg (base) and 75 mg (base), Strides Shasun said in a BSE filing.
The product is a generic version of Hoffmann-La Roche Inc's Tamiflu capsules, it added.
The product will be manufactured at the company's oral dosage facility at Bengaluru and will be marketed by Strides Pharma Inc in the US market, it added.
Shares of Strides Shasun today closed at Rs 349.65 apiece on BSE, down 2.25 per cent from its previous close.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)